Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4528MR)

This product GTTS-WQ4528MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4528MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5192MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ7149MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ10709MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ13523MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ6878MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ4011MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ14373MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ13339MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06801591
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW